Titan Pharma Inc (TTNP) 0.6600 $TTNP Titan Phar
Post# of 273256
Posted On: 10/11/2015 6:57:35 AM
Titan Pharma Inc (TTNP) 0.6600 $TTNP
Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of New Drug Application for Probuphine
Marketwired - Mon Sep 28, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) announced today that the U.S. Food and Drug Administration has accepted for review the New Drug Application (NDA) for Probuphine(R), a six-month subdermal implant containing buprenorphine hydrochloride for the long-term maintenance treatment of opioid addiction. Probuphine was developed utilizing Titan's long-term, continuous drug delivery technology, ProNeura(TM). The FDA has set Feb. 27, 2016 as a target date for action on the application, which was submitted by Titan's development and commercialization partner Braeburn Pharmaceuticals.
Titan Pharmaceuticals Announces Reverse Stock Split
Marketwired - Mon Sep 28, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology, announced today that it has filed an amendment to its certificate of incorporation that will effect a 1-for-5.5 reverse stock split of the company's authorized, issued and outstanding shares of common stock, warrants and options as of September 29, 2015. The reverse stock split is expected to become effective with the Financial Industry Regulation Authority (FINRA) and in the marketplace at the open of business on September 29th, whereupon the shares of common stock will begin trading on a split-adjusted basis.
Braeburn Announces FDA's Acknowledgment of Receipt of Probuphine® NDA Resubmission; Agency Action Expected by February 27, 2016
PR Newswire - Mon Sep 28, 6:00AM CDT
Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action. Probuphine®, licensed from Titan Pharmaceuticals, Inc. (OTCQB:TTNP), is an investigational, six-month buprenorphine HCl subdermal implant for the long-term maintenance treatment of opioid addiction. The Probuphine NDA resubmission includes results from a Phase 3 double-blind, double-dummy clinical study of Probuphine completed in May 2015.
Titan Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Thu Sep 03, 4:00PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that Sunil Bhonsle, president, will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10 at 3:25 p.m. at the St. Regis Hotel in New York. The presentation will take place in the Louis XVI B room.
Titan Pharmaceuticals Reports Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 3:30PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the second quarter ended June 30, 2015.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2015 Financial Results
Marketwired - Tue Aug 11, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Monday, Aug. 17, 2015 to discuss the company's financial results as of June 30, 2015. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Presents Nonclinical Data Supporting Use of ProNeura Drug Delivery Platform in Parkinson's Disease
Marketwired - Wed Jun 17, 11:32AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today presented nonclinical data at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego demonstrating the potential of Titan's ProNeura(TM) long-term, continuous drug delivery platform in the treatment of Parkinson's disease. ProNeura-based subdermal implants containing the dopamine agonist ropinirole were first characterized for pharmacokinetics of drug release in rats followed by an evaluation of motor function and onset of treatment-related dyskinesias in an implant dose-escalating study in the Parkinsonian monkey model.
Titan Pharmaceuticals' Positive Phase III Trial Creates Clear Path To Approval
Alexander Maxwell - at Seeking Alpha - Wed Jun 17, 11:22AM CDT
Titan Pharmaceuticals to Present at the BIO International Convention
Marketwired - Wed Jun 10, 2:04PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that President Sunil Bhonsle will present at the BIO International Convention 2015 being held June 16-18 at the Pennsylvania Convention Center in Philadelphia. The presentation will take place on Tuesday, June 16 at 4:15 p.m. in Theater 3.
Stock to Watch: Titan Pharmaceuticals Up 12.3% (TTNP)
Comtex SmarTrend(R) - Mon Jun 08, 10:18AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 12.3% to $0.90 on 6.4x average daily volume. Titan Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 365,000 shares per day. The stock has outperformed the Dow (12.3% to the Dow's -0.2%) and outperformed the S&P 500 (12.3% to the S&P's -0.2%) during today's trading.
Titan Pharma's Probuphine subdermal implant successful in Phase 3 study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 6:53AM CDT
Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle
at The Street - Mon Jun 08, 6:01AM CDT
Titan and its partner will resubmit Probuphine for FDA approval later this year.
Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Mon Jun 08, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today reported positive topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. This study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints. It was conducted by Titan's commercialization and development partner Braeburn Pharmaceuticals and developed in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study.
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction
PR Newswire - Mon Jun 08, 6:00AM CDT
Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine®, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. The study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints, which were established in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study. Braeburn has exclusive commercialization rights to Probuphine in the United States and Canada under a license from Titan Pharmaceuticals, Inc. (OTCQB: TTNP).
Titan Pharma schedules conference call for Monday am to discuss Probuphine Phase 3 results
Seeking Alpha - at Seeking Alpha - Fri Jun 05, 4:58PM CDT
Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Fri Jun 05, 3:36PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) announced today that it expects to report topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction, before the market opens on Monday, June 8, 2015.
Penny Stocks Research for Valmie Resources, EKSO BIONICS, NuGene, Titan Pharmaceuticals, Medican, and Auri
PR Newswire - Fri May 29, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), EKSO BIONICS (OTCBB:EKSO), NuGene (OTCBB:NUGN), Titan Pharmaceuticals (OTCMKTS:TTNP), Medican (OTCMKTS:MDCN), and Auri (OTCMKTS:AURI).
Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 5.7% (TTNP)
Comtex SmarTrend(R) - Thu May 21, 10:45AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.7% to $0.82 on 1.2x average daily volume. Thus far today, Titan Pharmaceuticals has traded 298,000 shares, vs. average volume of 242,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.3%) during today's trading.
Titan Prepares For Big Summer 2015
Jason Napodano, CFA - at Seeking Alpha - Sat May 16, 7:25AM CDT
Titan Pharmaceutical's (TTNP) Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 4:01PM CDT
Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of New Drug Application for Probuphine
Marketwired - Mon Sep 28, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) announced today that the U.S. Food and Drug Administration has accepted for review the New Drug Application (NDA) for Probuphine(R), a six-month subdermal implant containing buprenorphine hydrochloride for the long-term maintenance treatment of opioid addiction. Probuphine was developed utilizing Titan's long-term, continuous drug delivery technology, ProNeura(TM). The FDA has set Feb. 27, 2016 as a target date for action on the application, which was submitted by Titan's development and commercialization partner Braeburn Pharmaceuticals.
Titan Pharmaceuticals Announces Reverse Stock Split
Marketwired - Mon Sep 28, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology, announced today that it has filed an amendment to its certificate of incorporation that will effect a 1-for-5.5 reverse stock split of the company's authorized, issued and outstanding shares of common stock, warrants and options as of September 29, 2015. The reverse stock split is expected to become effective with the Financial Industry Regulation Authority (FINRA) and in the marketplace at the open of business on September 29th, whereupon the shares of common stock will begin trading on a split-adjusted basis.
Braeburn Announces FDA's Acknowledgment of Receipt of Probuphine® NDA Resubmission; Agency Action Expected by February 27, 2016
PR Newswire - Mon Sep 28, 6:00AM CDT
Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action. Probuphine®, licensed from Titan Pharmaceuticals, Inc. (OTCQB:TTNP), is an investigational, six-month buprenorphine HCl subdermal implant for the long-term maintenance treatment of opioid addiction. The Probuphine NDA resubmission includes results from a Phase 3 double-blind, double-dummy clinical study of Probuphine completed in May 2015.
Titan Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Thu Sep 03, 4:00PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that Sunil Bhonsle, president, will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10 at 3:25 p.m. at the St. Regis Hotel in New York. The presentation will take place in the Louis XVI B room.
Titan Pharmaceuticals Reports Second Quarter 2015 Financial Results
Marketwired - Thu Aug 13, 3:30PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the second quarter ended June 30, 2015.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2015 Financial Results
Marketwired - Tue Aug 11, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Monday, Aug. 17, 2015 to discuss the company's financial results as of June 30, 2015. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Presents Nonclinical Data Supporting Use of ProNeura Drug Delivery Platform in Parkinson's Disease
Marketwired - Wed Jun 17, 11:32AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today presented nonclinical data at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego demonstrating the potential of Titan's ProNeura(TM) long-term, continuous drug delivery platform in the treatment of Parkinson's disease. ProNeura-based subdermal implants containing the dopamine agonist ropinirole were first characterized for pharmacokinetics of drug release in rats followed by an evaluation of motor function and onset of treatment-related dyskinesias in an implant dose-escalating study in the Parkinsonian monkey model.
Titan Pharmaceuticals' Positive Phase III Trial Creates Clear Path To Approval
Alexander Maxwell - at Seeking Alpha - Wed Jun 17, 11:22AM CDT
Titan Pharmaceuticals to Present at the BIO International Convention
Marketwired - Wed Jun 10, 2:04PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that President Sunil Bhonsle will present at the BIO International Convention 2015 being held June 16-18 at the Pennsylvania Convention Center in Philadelphia. The presentation will take place on Tuesday, June 16 at 4:15 p.m. in Theater 3.
Stock to Watch: Titan Pharmaceuticals Up 12.3% (TTNP)
Comtex SmarTrend(R) - Mon Jun 08, 10:18AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 12.3% to $0.90 on 6.4x average daily volume. Titan Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 365,000 shares per day. The stock has outperformed the Dow (12.3% to the Dow's -0.2%) and outperformed the S&P 500 (12.3% to the S&P's -0.2%) during today's trading.
Titan Pharma's Probuphine subdermal implant successful in Phase 3 study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 6:53AM CDT
Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle
at The Street - Mon Jun 08, 6:01AM CDT
Titan and its partner will resubmit Probuphine for FDA approval later this year.
Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Mon Jun 08, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today reported positive topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. This study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints. It was conducted by Titan's commercialization and development partner Braeburn Pharmaceuticals and developed in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study.
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction
PR Newswire - Mon Jun 08, 6:00AM CDT
Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine®, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. The study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints, which were established in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study. Braeburn has exclusive commercialization rights to Probuphine in the United States and Canada under a license from Titan Pharmaceuticals, Inc. (OTCQB: TTNP).
Titan Pharma schedules conference call for Monday am to discuss Probuphine Phase 3 results
Seeking Alpha - at Seeking Alpha - Fri Jun 05, 4:58PM CDT
Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Fri Jun 05, 3:36PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) announced today that it expects to report topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction, before the market opens on Monday, June 8, 2015.
Penny Stocks Research for Valmie Resources, EKSO BIONICS, NuGene, Titan Pharmaceuticals, Medican, and Auri
PR Newswire - Fri May 29, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), EKSO BIONICS (OTCBB:EKSO), NuGene (OTCBB:NUGN), Titan Pharmaceuticals (OTCMKTS:TTNP), Medican (OTCMKTS:MDCN), and Auri (OTCMKTS:AURI).
Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 5.7% (TTNP)
Comtex SmarTrend(R) - Thu May 21, 10:45AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.7% to $0.82 on 1.2x average daily volume. Thus far today, Titan Pharmaceuticals has traded 298,000 shares, vs. average volume of 242,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.3%) during today's trading.
Titan Prepares For Big Summer 2015
Jason Napodano, CFA - at Seeking Alpha - Sat May 16, 7:25AM CDT
Titan Pharmaceutical's (TTNP) Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 4:01PM CDT
(0)
(0)Scroll down for more posts ▼